Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

Marc P. Girard; Valentina Picot; Christophe Longuet; Gary J. Nabel

doi:10.1016/j.vaccine.2013.02.067

Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

Marc P. Girard, Valentina Picot, Christophe Longuet, Gary J. Nabel

Research output: Contribution to journal › Article › peer-review

Abstract

The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). This paper, Part 2 of the report, focuses on potentially protective n-nAbs. Evidence was presented that n-nAbs may effectively contribute to protection against HIV, as illustrated by the recent RV144 efficacy trial. They can either act as IgGs by mediating antibody-dependent cellular cytotoxicity (ADCC) involving Fc effector functions, or as IgAs, particularly dimeric IgA1s, which can inhibit virus transcytosis through monocellular epithelia and could play an important role in mucosal immunity.

Original language	English (US)
Pages (from-to)	2984-2987
Number of pages	4
Journal	Vaccine
Volume	31
Issue number	29
DOIs	https://doi.org/10.1016/j.vaccine.2013.02.067
State	Published - Jun 24 2013
Externally published	Yes

Keywords

Antibody-dependent cellular cytotoxicity
HIV vaccines
Mucosal immunity
Transcytosis inhibitory antibodies

ASJC Scopus subject areas

Immunology and Microbiology(all)
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)
Molecular Medicine

Access to Document

10.1016/j.vaccine.2013.02.067

Fingerprint Dive into the research topics of 'Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.'. Together they form a unique fingerprint.

Cite this

Report of the Cent Gardes HIV Vaccine Conference : The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012. / Girard, Marc P.; Picot, Valentina; Longuet, Christophe; Nabel, Gary J.

In: Vaccine, Vol. 31, No. 29, 24.06.2013, p. 2984-2987.

Research output: Contribution to journal › Article › peer-review

@article{48337fe7cc6b438193ba0f96c71bf443,

title = "Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation M{\'e}rieux Conference Center, Veyrier du Lac, France 5-7 November 2012.",

abstract = "The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation M{\'e}rieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). This paper, Part 2 of the report, focuses on potentially protective n-nAbs. Evidence was presented that n-nAbs may effectively contribute to protection against HIV, as illustrated by the recent RV144 efficacy trial. They can either act as IgGs by mediating antibody-dependent cellular cytotoxicity (ADCC) involving Fc effector functions, or as IgAs, particularly dimeric IgA1s, which can inhibit virus transcytosis through monocellular epithelia and could play an important role in mucosal immunity.",

keywords = "Antibody-dependent cellular cytotoxicity, HIV vaccines, Mucosal immunity, Transcytosis inhibitory antibodies",

author = "Girard, {Marc P.} and Valentina Picot and Christophe Longuet and Nabel, {Gary J.}",

year = "2013",

month = jun,

day = "24",

doi = "10.1016/j.vaccine.2013.02.067",

language = "English (US)",

volume = "31",

pages = "2984--2987",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "29",

}

TY - JOUR

T1 - Report of the Cent Gardes HIV Vaccine Conference

T2 - The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

AU - Girard, Marc P.

AU - Picot, Valentina

AU - Longuet, Christophe

AU - Nabel, Gary J.

PY - 2013/6/24

Y1 - 2013/6/24

N2 - The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). This paper, Part 2 of the report, focuses on potentially protective n-nAbs. Evidence was presented that n-nAbs may effectively contribute to protection against HIV, as illustrated by the recent RV144 efficacy trial. They can either act as IgGs by mediating antibody-dependent cellular cytotoxicity (ADCC) involving Fc effector functions, or as IgAs, particularly dimeric IgA1s, which can inhibit virus transcytosis through monocellular epithelia and could play an important role in mucosal immunity.

AB - The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). This paper, Part 2 of the report, focuses on potentially protective n-nAbs. Evidence was presented that n-nAbs may effectively contribute to protection against HIV, as illustrated by the recent RV144 efficacy trial. They can either act as IgGs by mediating antibody-dependent cellular cytotoxicity (ADCC) involving Fc effector functions, or as IgAs, particularly dimeric IgA1s, which can inhibit virus transcytosis through monocellular epithelia and could play an important role in mucosal immunity.

KW - Antibody-dependent cellular cytotoxicity

KW - HIV vaccines

KW - Mucosal immunity

KW - Transcytosis inhibitory antibodies

UR - http://www.scopus.com/inward/record.url?scp=84879009992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879009992&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.02.067

DO - 10.1016/j.vaccine.2013.02.067

M3 - Article

C2 - 23602538

AN - SCOPUS:84879009992

VL - 31

SP - 2984

EP - 2987

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29

ER -